Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

ZT-1a

Catalog No. T39566 Copy Product Info
Purity: 99.74%
😃Good
ZT-1a is a SPAK inhibitor.ZT-1a inhibits SPAK.ZT-1a can be used for the prevention and treatment of neurodegenerative and neurocognitive disorders.

ZT-1a

Copy Product Info
😃Good
Catalog No. T39566

ZT-1a is a SPAK inhibitor.ZT-1a inhibits SPAK.ZT-1a can be used for the prevention and treatment of neurodegenerative and neurocognitive disorders.

ZT-1a
Cas No. 212135-62-1
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$74In StockIn Stock
5 mg$179In StockIn Stock
10 mg$289In StockIn Stock
25 mg$397In StockIn Stock
50 mg$569In StockIn Stock
1 mL x 10 mM (in DMSO)$198In StockIn Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.74%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
ZT-1a is a SPAK inhibitor.ZT-1a inhibits SPAK.ZT-1a can be used for the prevention and treatment of neurodegenerative and neurocognitive disorders.
In vitro
ZT-1a inhibits the Na-K-2Cl cotransporter (NKCC1) and stimulates the K-Cl cotransporter (KCC) by reducing its SPS1-related proline/alanine-rich kinase (SPAK) dependent phosphorylation[1].At 1 μM ZT-1a, NKCC1 p-Thr203/207/212 phosphorylation is inhibited by 72±5.2%, and in HEK-293 cells, KCC phosphorylation at sites 1/2 is inhibited by 65-77% at 3 μM ZT-1a[1].Phosphorylation of SPAK at the Ser373 site is inhibited by 70±3.8% at 3-10 μM ZT-1a[2].
ZT-1a (10 μM) inhibits NKCC1 but stimulates KCC3 activity[2].
In vivo
ZT-1a inhibits the SPAK-dependent upregulation of NKCC1 and KCC3 phosphorylation in ischemic brains.post-stroke treatment with ZT-1a protects both gray and white matter tissues in ischemic brains[1].
Chemical Properties
Molecular Weight445.73
FormulaC22H15Cl3N2O2
Cas No.212135-62-1
SmilesCc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(Cl)ccc1O
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 8 mg/mL (17.95 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.24 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.2435 mL11.2176 mL22.4351 mL112.1755 mL
5 mM0.4487 mL2.2435 mL4.4870 mL22.4351 mL
10 mM0.2244 mL1.1218 mL2.2435 mL11.2176 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy ZT-1a | purchase ZT-1a | ZT-1a cost | order ZT-1a | ZT-1a chemical structure | ZT-1a in vivo | ZT-1a in vitro | ZT-1a formula | ZT-1a molecular weight